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ABSTRACT 
Objective: Therapeutic drug monitoring (TDM) of antiepileptic drugs 
(AEDs) is widely established for older generation AEDs, whereas there is 
limited evidence about newer AEDs. Our aim is to assess the benefit of newer 
generation AEDs TDM in epilepsy.  
Methods: We performed a randomised, controlled trial comparing 
systematic with rescue TDM of lamotrigine, levetiracetam, oxcarbazepine, 
topiramate, brivaracetam, zonisamide, or pregabalin. Participants were adults 
with epilepsy, in whom treatment with newer generation AEDs was initiated or 
needed adjustment. In the systematic TDM arm, AED plasma levels were 
available at each appointment, whereas in the rescue TDM arm, levels were 
known only if a study endpoint was reached (inefficacy or adverse events). The 
primary outcome was the proportion of participants followed over one year 
without reaching one of the predefined endpoint. 
Results: 151 participants were enrolled; global retention in the study was 
similar in both arms (56% overall, 58% in the systematic and 53% in rescue 
TDM arm, p=0.6 Cox regression). There was no difference in term of outcome 
regarding treatment efficacy or tolerability. Partial adherence of clinicians to 
TDM (adjusting or not AED dosage based on blood levels) did not explain this 
lack of benefit. 
Interpretation: This study provides Class A evidence that systematic drug 
level monitoring of newer generation AEDs does not bring tangible benefits in 
the management of patients with epilepsy. Poor correlation between clinical 
effects and drug levels likely accounts for this finding. However, TDM is useful 
in several situations, such as pregnancy, as well as compliance issues. 
 
 
Key words: efficacy, adverse events, antiepileptic drug blood levels, 
pharmacokinetic, prospective.  
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INTRODUCTION: 
In clinical practice, therapeutic drug monitoring (TDM) is useful to adjust 
medication dosages of treatments that have large inter-individual and low intra-
individual pharmacokinetic variability, show a good correlation between plasma 
concentrations and clinical effects, and have a narrow therapeutic index 1,2. 
Therapeutic drug monitoring (TDM) of older generation antiepileptic drugs 
(AEDs) such as phenytoin (PHT), carbamazepine, phenobarbital (PB) or 
valproate, has been widely implemented since 1960. The relationship between 
AEDs plasma levels and clinical effect has been well established for those 
agents, allowing to define reference ranges which are widely accepted 3–8.  
The use of older generation AEDs is decreasing as newer generation 
AEDs are being increasingly prescribed9, mostly because of their better 
tolerability profile. In this evolving situation, the International League Against 
Epilepsy (ILAE) published recommendations for the use of TDM 10. Evidence 
about TDM in newer generation AEDs is however very scarce. Observational 
studies showed a correlation between plasma concentration and clinical 
response for lamotrigine (LTG) 11–13, levetiracetam (LEV) 14,15 and topiramate 
(TPM) 16–19, whereas for others (brivaracetam (BRV), lacosamide (LCM), 
pregabaline (PGB), zonisamide (ZNS), perampanel (PER), oxcarbazepine 
(OXC)) this relationship remains controversial 2,20–22. Some of these AEDs, such 
as LTG, LCM, ZNS, or felbamate, show significant inter-individual 
pharmacokinetic variability due to interactions or metabolism polymorphisms, as 
they are substrates of hepatic cytochromes or glucuronyltransferases. Other 
newer generation AEDs have less pharmacokinetic variability (LEV, TPM, 
OXC), but still show significant changes in their bioavailability with certain co-
medications or under specific physiological modifications, such as pregnancy 23–
25.  At times, those pharmacokinetic changes may exert dramatic consequences 
26,27.  
TDM utility for newer generation AEDs was never assessed in a controlled 
trial. Its usefulness tends however to be accepted and its use is even 
recommended in specific situations, such as pregnancy 28.  
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The aim of this study was to assess whether the systematic monitoring of 
newer generation AEDs plasma levels provides a tangible benefit in the care of 
patients with epilepsy.  
METHODS:  
We set up a randomised controlled two-arm clinical trial comparing 
systematic versus rescue TDM (ration 1:1). In the rescue TDM arm, medication 
plasma levels were available only when one of the specific predefined endpoint 
for failure was reached (status epilepticus, ≥2 seizures with loss of awareness 
during one year of follow-up, need to add-on a further AED or to discontinue the 
study drug because of predefined inefficacy or poor tolerability). 
The study was approved by the ethical committee of our institution (2015-
00079) and it was registered in the clinicalTrials.gov database (NCT02739282). 
The study was independently monitored, and funded by the Swiss National 
Scientific Foundation (grant 320030_163430). 
 
Participants 
Participants were consenting patients older than 18 years of age, 
diagnosed with epilepsy and followed in our outpatient clinic. They were treated 
with newer generation AEDs on mono- or poly-therapy (LTG, LEV, LCM, OXC, 
TPM, ZNS, BRV, PER), either starting a treatment or requiring dosage 
adjustment because of inefficacy or adverse events. Pregnant women, in whom 
systematic TDM is recommended 28, were excluded. The study was presented 
by JN, AOR, AFH, and PR to the potential participants.  
 
Protocol 
Participants were randomized 1:1 (following a predefined randomisation 
list) either into the systematic or rescue TDM arm. Allocation was in a list 
covered with paint, which had to be scratched. The randomisation list was 
organised in cluster and done by the pharmacists (T.B. and P.A.). Each patient 
was followed for a studied period of one year with visits set as required 
clinically, usually 3 to 4 times per year. Participants in both arms had blood 
samples taken at each visit. Time interval between visits was established by the 
treating physician according to clinical needs. The participants were instructed 
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to take their medication at least 6 hours before or after the visit to avoid peak 
level at the sampling time. All blood samples were collected at steady state after 
the last dosage adjustment.  
A pharmacist specialised in TDM (P.A.) and a neurologist (I.A.R.) 
assessed all plasma levels to ascertain if concentrations were within the 
reference ranges, taking into account the time of the last dosing and the 
medication pharmacokinetics. ILAE recommended reference ranges were used 
(table 2) 10.  In the systematic TDM arm, results were systematically 
communicated to the clinician in charge of the patient within 24 hours. We did 
not provide target levels to clinicians in the systematic TDM arm, but we 
compared drug levels (after extrapolation of trough levels when needed) with 
ILAE recommended reference ranges (table 2) 10. Clinicians were then free to 
adjust medication using these results. In the rescue TDM arm, drug levels were 
blinded to the physicians during the study follow-up, AED serum levels were 
communicated to the treating physician only if a study endpoint (see below) was 
reached. Otherwise, the results became available only at the end of the follow-
up period. Therefore, in systematic TDM arm, drug levels were available for the 
clinician at each, whereas in the rescue TDM arm, drug levels were available 
only if the treatment failed and needed to be rescued. The rescue TDM arm 
assessed therefore the management of patients without drug levels available; 
once an endpoint was reached, drug levels would be available in that arm at the 
same time the patient would be excluded from the study (drug levels and 
dosage adjustment performed thereafter would not be considered as part of the 
outcome). In both arms, clinicians in charge were free to adjust the treatment 
dosage based on their clinical judgement (for example, if the patient suffered 
from adverse events AED doses were decreased or AED was stopped and 
changed), but, as designed, knowledge of drug level was available only for 
patients in the systematic TDM arm. The inclusion period lasted 18 months and 
the follow-up 1 year.  
At the first visit, demographic data, epilepsy characteristics, current and 
previous treatments were recorded. At later visits, adverse events and seizure 
frequency, as well as treatment changes were recorded. The final visit occurred 
at the end of the 1-year follow-up or when an endpoint was reached.  
 6
A combined endpoint (representing treatment failure) was used as the 
primary outcome of the trial, accounting for both efficacy and adverse events. It 
was defined by the occurrence of any of: ≥ 2 seizures with impaired awareness 
(with generalised tonic-clonic seizures), status epilepticus (defined as any 
seizure lasting >5 minutes), need of an add-on AED, or need to discontinue the 
studied drug (for either lack of efficacy or adverse reactions); the last two 
criteria were left to the clinician’s judgement. Severe adverse events were 
defined as hospitalisation or urgent medical visit, death, life-threatening 
condition, or condition leading to a persistent disability. Upon occurrence of an 
endpoint, the participant would be taken off study with drug levels being made 
available to the clinician in charge of the patient. We recorded the retention of 
participants, defined as time of follow-up in the study without reaching any of 
the previous endpoints. In the rescue group, once the patient got an endpoint 
and the AED levels were available, if there was AED levels equal 0 or very low, 
then the patient was contacted and asked by the compliance. When the 
compliance was bad the AED doses were maintained, and when the 
compliance was good we suspected a fast inducer metabolization and the dose 
was increased.  
 
Determination of plasma AED levels 
Plasma levels were determined in the clinical pharmacology laboratory of 
our institution, which developed an Ultra-performance liquid Chromatography 
coupled to tandem Mass Spectrometry (UPLC-MS/MS) method, requiring 100 
µL of plasma for simultaneous quantification within 7 min of the AEDs 29. Quality 
controls/certification in external laboratories were regularly performed. 
 
Statistical analysis 
Our inclusion target was 150 participants to have sufficient power to 
demonstrate a 20% difference in treatment failures. 
Retention in the study without reaching a predefined endpoint was 
assessed using survival analysis. Systematic TDM and rescue TDM were 
compared using Cox Regression. The outcome was analysed taking into 
account all patients included (“intention to monitor”) as well as considering only 
patients who followed the protocol (“per protocol”). Subgroup analysis ( drug 
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resistant epilepsy, focal or generalized epilepsy, patients on monotherapy or 
polytherapy, patients included due to dosage adjustment or to start of a new 
AED, patients treated with LTG) were analysed as secondary outcomes. 
Pearson Chi squared and Mann Whitney U tests were used in univariable 
analyses. P values < 0.05 were considered as significant. All analyses were 
performed using SPSS version 25 (IBM Inc).  
 
RESULTS 
Patients 
We enrolled 151 patients between June 2016 and December 2017, the 
overall flow of the trial is shown in figure 1; demographic details of all 
participants are shown in table 1. Both groups were comparable with respect to 
age, sex, origin, type of epilepsy, drug resistant epilepsy, epilepsy duration and 
number of previously tried AEDs. Most had a focal epilepsy (75.5%) and half of 
the patients had drug resistant epilepsy, according to ILAE’s definition of two 
adequate AEDs failing to fully control epilepsy 30. Most prescribed AEDs were 
LTG (66 participants) and LEV (31), followed by ZNS (21), TPM (9), LCM (6) 
and OXC (4). Half (55%) of the participants were treated with monotherapy. 
Considering inclusion criteria, 87 (57%) patients were enrolled because of 
dosage adjustments and 64 (42%) because of introduction of a new AED, of 
which 17 (26%) were drug naïve. 
 
Outcome 
 Global retention rate was 56%: 69 patients completed the one-year 
follow-up without reaching an endpoint. In the “intention to monitor” analysis, 
both arms had similar retention rates (58% in the systematic TDM arm versus 
53% in the rescue TDM arm, p=0.6, Cox regression, figure 2). Among the 61 
participants with endpoints, 34 (55.7%) had ≥2 seizures with loss of awareness, 
18 (29.5%) reported adverse events requiring treatment changes, 8 (13.1%) 
required treatment changes because of inefficacy, and 1 (0.01%) had focal 
status epilepticus.  
In the “per protocol” analysis (figure 1), the overall retention was 56%, 
without significant difference between systematic (58%) and rescue (55%) TDM 
arms (p= 0.7, Cox Regression). Retention rates between the two arms were not 
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different in subgroups (systematic vs rescue arm): drug-resistant epilepsy (60% 
in systematic vs 47% in rescue arm, p=0.3); focal epilepsy (58% in systematic 
vs 57% in rescue arm, p=0.9); generalized epilepsy (58% in systematic vs 49% 
in rescue arm, p=0.6); participants on mono-therapy (82% in systematic vs 70% 
in rescue arm, p=0.3), or polytherapy (36% in systematic vs 35.5% in rescue 
arm, p=0.9); participants included for dosage adjustment (52% in systematic vs 
49% in rescue arm, p=0.7); participants included for starting an AED (73% in 
systematic vs 65% in rescue arm, p=0.6), drug naïve patients (85% in 
systematic vs 90.5% in rescue arm, p=0.3); and participants treated with LTG 
(53% in systematic vs 56% in rescue arm, p=0.7). 
 
Plasma drug levels 
All AED blood were measured at least 6 hours after the last dosing, 166 
(out of 400, 41.5%) were trough levels. 
In the “per protocol” analysis, every participant had at least one AED 
plasma level. Considering all plasma levels of all AEDs in each participant over 
the follow-up period, the median proportion of drug levels within the reference 
ranges per participant was 0.5 (range: 0-1). When stratifying all participants 
according to their proportion of plasma levels within the reference ranges into 
high (≥ 50%) or low (<50%), there was no difference of retention between 
participants with a high proportion of drug levels within the range (52%) versus 
those with a low proportion (59%) (p=0.5, Cox Regression). 
In order to analyse the impact of TDM in the systematic TDM arm, we 
calculated the proportion of prescribed dosage changes for each participant 
with the aim of bringing serum levels within the reference range (typically, 
increasing dosage when the drug level was below the reference range), as 
opposed to when those changes were not prescribed, or when they were not 
aimed at bringing drug levels within the ranges. Taking into consideration all 
changes made for all medications over the follow-up period, the median 
proportion of changes aimed at bringing drug level in the reference ranges was 
0.5 (range: 0-1). When comparing retention rate of participants with a high (≥ 
50%) proportion of changes targeting the references ranges and those with a 
low proportion (<50%), there was no significant difference (58% vs 70%, p=0.7)   
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We assessed the proportion of medication changes prescribed by 
physicians in each arm. After the initial change which was the inclusion 
criterion, 43 dosages adjustments were prescribed in the systematic arm during 
the follow-up in 32 participants (out of 58, 55%) and 38 adjustments were made 
in the rescue arm in 31 participants (out of 59, 53%). There was no significant 
difference between both arms (p=0.3 chi squared). 
We classified adjustments made at each visits in three of the different 
categories: treatment increase when medication(s) dosage was only increased; 
treatment decrease when medication(s) dosage was only decreased and 
balanced changes when some of the medications dosage were increased 
whereas others were decreased. In a total 81 changes during the follow-up in 
both arms: treatment increase accounted for 39.1% of changes in the 
systematic arm, 40.6% to the rescue arm, treatment decrease for 17.2% in the 
systematic arm, 11.8% in the rescue arm; balanced changes for 43.1% in the 
systematic arm and 47.4% in the rescue. There was no difference between both 
arms (p=0.7, Chi Squared). 
The median number of visits (and TDM for systematic arm) was 3 in both 
arms. The median interval between TDM/visits in both the systematic and the 
rescue arm was 91.3 days (range 10.5-186 in the systematic arm, range 9.5-
130.6 in the rescue arm, p=0.9).  
 
Efficacy 
When all inefficacy endpoints were being considered together (occurrence 
of seizures with loss of awareness, need to change treatment because of 
insufficient efficacy, occurrence of status epilepticus), there was no retention 
difference between systematic (65%) and rescue TDM arms (66%, p= 0.9) in 
the per protocol analysis. When considering the most commonly prescribed 
AED (LTG, n=49), last plasma levels in participants who had an inefficacy 
endpoint (median: 3.5 mg/L, range: 0.8-12.2) were not different to last plasma 
levels in participants without such endpoints in both arms (2.2 mg/l, 0-17.9, 
p=0.3, Mann Whitney). Similarly, there was no difference for participants on 
LEV (n=20; median: 10.9 mg/L, range 0-20.3 vs 7.9 mg/L, 1.2-33.6, p=0.6, 
Mann Whitney). 
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Adverse events 
In the per protocol analysis, 45% of participants reported an adverse event 
at least once (leading to an endpoint or not) during the follow-up period. Most 
common features were tiredness (25%), psychiatric symptoms (depression, 
aggressiveness, 23%), weight changes (17%), and unsteadiness (13%). The 
retention in both arms when considering only patients having toxicity endpoints 
(18) was similar in systematic (90%) and in rescue TDM (85%) (p=0.4). The 
occurrence of serious adverse events was also similar in both arms (3.9% in 
systematic vs 1.3% in rescue TDM, p= 0.6 Chi Square) over the entire follow-
up. There was no difference in last LTG plasma levels in participants who 
reported adverse events endpoints (median: 1.7 mg/L, range: 0-17.9) when 
compared with last plasma levels of participants without this endpoint, in both 
arms (2.7 mg/L, 0.7-12.5, p=0.8, Mann Whitney). There was also no difference 
between arms for participants on LEV (n=20; 4.4 mg/L, range 1.2-7.7 mg/L vs 
8.9, range 0-20.3 mg/L, p=0.2, Mann Whitney).  
 
DISCUSSION 
This trial does not show any significant benefit of systematic TDM of 
newer generation AED in an outpatients setting compared to rescue TDM, 
representing TDM as it is widely used in clinical practice. Retention was similar 
in both groups (59% in the systematic TDM group versus 56%). These results 
suggest that continuously monitoring drug levels provides at most a modest 
benefit in the outcome of patient with epilepsy. There was no particular 
subgroup benefitting of systematic TDM.  
Retention in the monotherapy group (76%) and in drug naive participants 
(90.9%) were greater than the global retention as a favourable outcome (at 
least in term of seizure control) is more likely in these patients31, with no 
difference between both arms. We also failed to find a difference between both 
arms in participants with drug resistant epilepsy, a group in which one might 
have expected that finer medication dosage adjustment might have been more 
useful given the greater prevalence of polytherapy and their risk of drug-drug 
interactions 32. There was also no benefit of systematic TDM in term of efficacy 
or tolerability, respectively.  
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The overall retention in the study (56%) was comparable with a similar 
clinical trial assessing the benefit of TDM of older generation AEDs 33, and with 
retention studies assessing add-on newer generation AEDs 34,35, supporting the 
generalizability of our observations. Our methodology was comparable to the 
two previous clinical trial of older generation AED TDM 33,36. In those studies, 
however, the treating physician was invited to modify the dosage of patients in 
the systematic TDM arm in order to achieve concentrations within the reference 
ranges. We chose a more pragmatic approach letting the clinician decide 
whether to adjust dosages, taking into account the overall context of the patient 
with the knowledge of drug level compared to the reference range.   
Despite the negative results of the previous clinical trials, older generation 
AEDs TDM is widely established in clinical practice, at least for PHT 3,4,37–39. 
TDM usefulness for CBZ and VPA is not clear 5,7,33,36,40. Several limitations of 
previous as well as our TDM trial may explain these negative outcomes. The 
adherence of clinicians to adjust dosage according to AED plasma levels was 
questioned 41. Despite being invited to do so, several authors pointed out that a 
substantial proportion of drug levels fell below or above the reference range in 
the previous trials 10, suggesting adjustments after TDM may not have been 
performed systematically. Another retrospective study suggested that modifying 
dosage (for PHT and PB) according to plasma levels is associated with a better 
outcome in term of seizure frequency and adverse events 41; interestingly, TDM 
adherence (adjusting AED doses based on TDM) by physicians was not a 
determinant of the outcome when comparing high versus low adherence in our 
study. Physicians might also have learned from TDM in clinical practice and 
published studies to anticipate AED pharmacokinetic changes, and they may 
adjust AED dosage reasonably well without knowing actual drug levels. Another 
more likely explanation for our negative findings on newer AEDs is the poor 
correlation between clinical effects and AEDs levels 20,21. We did indeed not find 
any differences of drug levels (for LTG and LEV), in participants reporting 
treatment failure, either in term of efficacy or tolerability. Maximal (ceiling) AED 
levels associated with remission 42,43 might have provided better references in 
regards of the endpoints of the trial. It was indeed shown that patients may 
reach optimal seizure control with AED plasma levels often below reference 
ranges 44–46. Individual reference ranges (referring to drug levels associated 
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with a response in an individual patient) might be also more useful in clinical 
practice 10,39,47–49, but assessing this aspect went beyond our aims.  
Our trial assessed the general systematic use of TDM for dosage 
adjustment, there are however situations in which TDM might be potentially 
useful: when toxicity is suspected in patients with intellectual disability in whom 
assessment of adverse effects is difficult; in lack of efficacy despite appropriate 
dosages; if compliance issues or drug interactions are suspected; in pregnancy; 
or in case of renal or hepatic dysfunction. When initiating therapy, individual 
variability also makes targeting a drug level more desirable than a dosage, 
there is however that this translates in clinical benefit 10. 
 Our trial has limitations. Due to regulatory issues, its design excluded 
patients unable to consent, such as those with intellectual disability or cognitive 
decline, which might represent important groups for TDM, as those patients are 
less able to report adverse events10.  Intervals between visits were also 
irregular, as we chose to remain as pragmatic as possible to maximise 
adherence with trial protocol. Reflecting clinical practice, blood samples were 
drawn during the time the participants spent in clinic, drug levels were therefore 
not for half of them trough concentrations. Participants were however instructed 
not to take their medication when coming at the morning clinic, blood samples 
were drawn at least 6 hours after dosing, and were then interpreted taking into 
account last dosing and medication pharmacokinetics. The endpoints we chose 
were also more stringent than those used in the previous trials, particularly 
occurrence of ≥2 seizures with loss of awareness in patients with drug resistant 
epilepsy. In previous trials, endpoints were typically the need to switch or to add 
another AED because of toxicity or inefficacy without clearer criteria 33,36. The 
endpoints we chose seem however more likely to reflect on a real benefit in 
patients’ quality of life, such as the return of the ability to drive.  
The sample size may also limit the ability to show a small significant 
difference between both arms; but the intervention effect is likely to be small. 
The trial included all newer generation AEDs available at the time of study, 
making it a heterogeneous group of drugs to assess. Some of these 
compounds are likely to be better candidate for TDM, such as LTG. We did 
however not find any obvious difference when analysing individually LTG and 
LEV, although the sample size was not large enough to drive firm conclusions. 
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We could not analyse specific value of systematic TDM for topiramate, 
oxcarbazepine or lacosamide, due to the small sample size, so usefulness of 
TDM of these AEDs is unclear.  Another important limitation is that the treating 
physicians were experienced neurologist specialised in epilepsy, our finding 
could therefore not be applied to patients treated by general neurologists and 
primary care physicians. Our study also assessed the usefulness of TDM to 
prevent treatment failure (as defined by our endpoints), but it did not assessed 
TDM potential benefit after the treatment failed. Our trial assessed the general 
systematic use of TDM for dosage adjustment, there are however situations in 
which TDM might be useful; when toxicity is suspected in patients with 
intellectual disability in whom assessment of adverse effects is difficult; in lack 
of efficacy despite appropriate dosages; if compliance issues or drug 
interactions are suspected; in pregnancy; or in case of renal or hepatic 
dysfunction. When initiating therapy, individual variability also makes targeting a 
drug level more desirable than a dosage, there is however no evidence that this 
translates in clinical benefit. 
In summary, systematic TDM of newer generation AEDs in patients with 
epilepsy appears unlikely to bring any tangible benefit in clinical practice; 
systematic monitoring of newer generation is therefore not justified. TDM should 
be reserved for selected situations such as pregnancy/pharmacokinetic 
changes, drug interactions or renal or hepatic failure, suspicion of non-
compliance, suspicion of toxicity, lack of effect in spite of correct 
dosages2,10,47,48,50.  
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Figure legends:  
 
Figure 1: Flow diagram of the study. The single death was not related to 
the study (brain tumour progression). 
Figure 2: Overall retention in both arms (“intention to monitor” analysis). 
There was no difference between the systematic TDM arm (58%) and the 
rescue TDM arm (53%, p= 0.5 Cox regression). 
 
 
 
 
Table 1: Demographic characteristics of participants according to their 
randomization. *Combination of all inefficacy endpoints: patients (≥2) with loss 
of awareness, status epilepticus and need to add a treatment because of 
inefficacy.  
 
 Total 
(151) 
Systematic 
TDM arm 
(76) 
Rescue 
TDM arm 
(75) 
P 
value 
Test used 
Sex (female) 
55.6% 55.3% 56% 0.9 
Pearson’s 
Chi Square 
Age, median, 
(range) 37(18-82) 38 (18-82) 36 (18-76) 0.5 
U Mann 
Whitney 
Focal 
epilepsy 75.5% 76.3% 74.7% 0.8 
Pearson’s 
Chi Square 
Drug-
resistant 
epilepsy 
48.7% 46.7% 50.7% 0.6 
Pearson’s 
Chi Square 
Epilepsy 
duration- 
years 
median, 
(range) 
7 (0-47) 8 (0-44) 7 (0-47) 0.7 
U Mann 
Whitney 
Number of 
previously 
tried AEDs  
median, 
(range) 
1 (0-9) 1 (0-7) 1 (0-9) 0.3 
U Mann 
Whitney 
All inefficacy 
endpoints* 43 (28.5%) 24 (31.6%) 
19 
(25.3%) 0.4 
Pearson’s 
Chi Square 
Adverse 
event 
endpoints 
18 
(12%) 7 (9.2%) 11(14.6%) 0.6 
Pearson’s 
Chi Square 
 
 
Table 2: AED and ILAE recommended reference ranges (Patsalos, 
Epilepsia 2008, Patsalos Seeizure 2014, Patsalos Therapeutic drug 
monitoring 2018) 
 
Antiepileptic drug Reference range 
Brivaracetam (BRV) 0.4-1.2 mg/L 
Lacosamide (LCM) 10-20 mg/L 
Lamotrigine (LTG) 2.5-15 mg/L 
Levetiracetam (LEV) 12-46 mg/L 
Oxcarbazepine (OXC) 3-35 mg/L 
Perampanel (PER) 180-980 μg/L 
Pregabaline (PGB) 2.8-10 mg/L 
Topiramate (TPM) 5-20 mg/L 
Zonisamide (ZNS) 10-40 mg/L 
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Figure 1: Flow-diagram of the study. The single death was not related to the 
study (brain tumour progression). 
 
Included and 
randomized: 
 151 
Systematic TDM: 
76  
Rescue TDM: 75  
Follow-up 
Ended	study	prematurely	
without	endpoints:	11 
• Death: 1 
• Diagnosis change: 1  
• Consent withdrawal: 3 
• Loss of follow-up: 6 
Ended	study	prematurely	
without	endpoints:	7 
• Consent withdrawal: 2 
•  Loss of follow-up: 5  
“Intention to monitor” analysis: all participants (151) 
Analysed:	58 
Excluded from this analysis:  
• Premature end 
without endpoint (see 
above): 11 
• No plasma levels: 4 
• Prescribed changes 
not followed: 3 
Analysed:	59 
Excluded from this analysis:  
• Premature end without 
endpoint (see above): 7 
• Pregnancy during 
study: 2 
• No plasma levels: 3 
• Prescribed changes not 
followed: 4 
Per protocol 
analysis: 117 
participants 
 
 
 
 
 
 Figure 2: Retention (56%) without endpoints, taking into account all participants 
(“intention to monitor” analysis). 
 
 
 
 
 
 
  
Figure 3:  Overall retention in both arms (“intention to monitor” 
analysis). There was no difference between the systematic TDM 
arm (58%) and the rescue TDM arm (53%, p= 0.5 Cox regression). 
 
 
 
 
